P21 vs Semax
Emerging vs Well Studied
compatible Different nootropic mechanisms; may complement each other.
Molecular Data
P21 Semax
Weight ~1,100 Da 813.93 Da
Half-life Over 3 hours (mouse plasma) 0.5-2 hours
Chain — 7 amino acids
Type CNTF-derived peptide ACTH(4-10) synthetic analog
Key Benefits
P21
01 Potent promotion of neurogenesis in the dentate gyrus
02 Increased BDNF expression
03 Reduced tau protein pathology
04 Reduced amyloid-beta plaque formation
05 Improved cognitive function and memory
06 Restored synaptic deficits in cortex and hippocampus
07 Reduced mortality rate in AD models
08 Crosses blood-brain barrier effectively
Semax
01 Rapid brain delivery via intranasal route
02 Rapidly increases BDNF levels
03 Extensive clinical research in Russia
04 Easy self-administration
05 Modulates dopamine and serotonin systems
06 Neuroprotective effects
Dosing Protocols
P21
Research compound - dosing not established for humans / Daily in animal research protocols
Research protocol Variable by study Daily
Semax
300-600mcg per dose (up to 1000mcg for intensive use) / 1-2x daily (morning recommended for cognitive boost)
Research protocol 500-750mcg 1x daily
Intensive protocol 750-1000mcg 1-2x daily
Side Effects
P21
Limited data - primarily preclinical research
Generally well-tolerated in animal studies
Semax
Mild nasal discomfort (nasal route)
Possible nasal sensation upon administration
Contraindications
Not approved for human use
Pregnancy or breastfeeding
Unknown safety profile in humans
Pregnancy or breastfeeding
Known peptide allergies
Do not exceed 4-week continuous use without medical supervision
Research Evidence
P21 Semax
Status Emerging Well Studied
References 4 studies 4 studies
Latest — 2021
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.